Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on June 14, 2017. The filing primarily addresses Item 8.01 (Other Events) regarding the commencement of an underwritten public offering of common stock and the termination of a specific "at-the-market" (ATM) offering program.
Key Financial Metrics and Capital Activities
- ATM Offering Proceeds: Between April 1, 2017, and June 7, 2017, the Company issued 3,170,931 shares of common stock.
- Average Sale Price: $3.86 per share.
- Net Proceeds: Approximately $11.9 million.
- Commission: The Company paid a 3% commission on gross proceeds to Cantor Fitzgerald & Co.
- Outstanding Shares: As of June 12, 2017, there were 97,701,431 shares of common stock outstanding.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin data for the period.
- Debt and Liquidity: The filing text does not provide specific debt or liquidity metrics beyond the recent equity raise.
Material Changes
- Termination of ATM Program: The Company terminated the ATM Prospectus Supplement (which allowed for up to $60.0 million in sales) on June 14, 2017. The underlying Sales Agreement with Cantor Fitzgerald remains in full force and effect.
- New Offering: The Company announced the commencement of a new underwritten public offering of common stock pursuant to a shelf registration statement (Form S-3) declared effective in November 2014.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or detailed risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities outside of a written prospectus meeting Section 10 requirements of the Securities Act.
Investor Verification Checklist
- Verify the terms and pricing of the new underwritten public offering announced on June 14, 2017, via the attached press release (Exhibit 99.1).
- Confirm the remaining capacity under the active Sales Agreement with Cantor Fitzgerald following the termination of the specific $60.0 million ATM Prospectus Supplement.
- Review the Company's most recent 10-Q or 10-K filings for comprehensive revenue, cash flow, and debt data not included in this 8-K.
- Monitor the dilution impact of the 3,170,931 shares issued during the April-June 2017 period against the 97.7 million shares outstanding.